摘要
目的:研究重组人白细胞介素11(recombinanthumaninterleukin11,rhIL11)对恶性肿瘤患者化疗后血小板计数和平均血小板体积的影响。方法:对65例肿瘤化疗患者,随机分成两组,实验组33例,化疗当天开始,每天皮下注射rhIL111.5mg,连续7d;对照组32例,为单纯化疗组。每周观察rhIL11对血小板计数的影响,连续3周。结果:实验组化疗后血小板计数和平均血小板体积分别达到(86.00±16.21)×109L-1和(11.43±2.48)fL,对照组为(79.45±15.46)×109L-1和(10.69±2.33)fL,rhIL11开始使用后1周,实验组血小板计数上升至(92.05±2.14)×109L-1,2周后血小板计数上升至正常水平(150.87±49.74)×109L-1。与对照组比较,rhIL11可提高化疗后患者血小板计数并能预防化疗后患者血小板的减少;而rhIL11对白细胞计数和血红蛋白浓度没有明显影响。结论:rhIL11可预防恶性肿瘤患者化疗后血小板的减少,并能促进化疗后血小板的恢复。
OBJECTIVE： To study the effects of recombinant human interleukin-11 （rhlL-11） on platelet in cancer patients after chemotherapy. METHODS： Sixty-five cancer patients who accepted chemotherapy were randomly divided into two groups： 23 patients accepted rhlL-11 therapy served as experiment group , 1.5 mg hypodermic for 7 days. 32 served as blank control group. Platelet number and mean platelet volume were counted every week for 3 times. RESULTS： Chemotherapy decreased platelet number. The platelet number was decreased to （86.00±16. 21）×10^9L^-1 after the chemotherapy, （79.45±15. 46）×10^9L^-1 in control group. One week after rhlL-11 therapy, the platelet number was increased （92.05±2.14fL）. Two weeks after rhlL-11 therapy, the platelet num- ber was increased to normal level （150.87±49.74） ×10^9L^-1. Compared with the control group, rhlL-11 significantly increased platelet number, rhlL-11 had no effect on white blood cell number and hemoglobin. CONCLUSION： rhIL-11 could prevent platelet from number decreasing and increase platelet number after chemotherapy in cancer patients.
出处
《中华肿瘤防治杂志》
CAS
2006年第12期929-930,共2页
Chinese Journal of Cancer Prevention and Treatment
